^
Association details:
Biomarker:BRAF mutation + TERT −146C>T
Cancer:Melanoma
Drug Class:BRAF inhibitor +
MEK inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro

Published date:
05/24/2023
Excerpt:
In this cohort, 45 patients received a combination of BRAF and MEK inhibitors for metastatic BRAF-mutated melanoma….In patients with the wild-type TERT promoter, the median PFS was 13 months while it was 4.9, 5.3 and 3.9 months in patients with −124C > T, −146C > T and −138/−139CC > TT-mutated TERT promoter, respectively (p = 0.06).
DOI:
10.3390/cancers15112888